microRNA-22与肝癌细胞侵袭的相关性

MicroRNA -22 Inhibits the Invasion of Hepatocellular Carcinoma

目的 探讨microRNA-22（miR-22）对肝癌细胞侵袭的表达量的变化及意义.方法 通过培养不同迁移和侵袭能力肝癌细胞系MHCC97L和HCCLM9细胞以及正常肝细胞系LO2细胞,比较miR-22表达量的差异.选取miR-22表达量相对较低的肝癌细胞系HCCLM9,向其转染miR-22抑制剂（inhibitor）和模拟物（mimics）,对比转染前后HCCLM9细胞系迁移能力的改变.采用实时荧光定量PCR（qRT-PCR）技术检测miR-22的表达量.采用划痕实验检测细胞迁移能力的改变.结果 与正常肝细胞系LO2细胞相比较,肝癌细胞系内miR-22表达量显著降低（P〈0.05）;且具有高侵袭能力的HCCLM9细胞相比低侵袭能力的MHCC97L细胞的miR-22表达量更低（P〈0.05）.向高侵袭能力的HCCLM9细胞转染miR-22 inhibitor后,细胞内miR-22表达量显著下降（P〈0.001）,细胞迁移能力显著增强（P〈0.001）;而转染miR-22 mimics之后,细胞内miR-22表达量显著升高（P〈0.001）,细胞迁移能力则显著减弱（P〈0.001）.结论 miR-22可抑制肝癌细胞迁移和侵袭能力,进而抑制肝癌的转移.

Objective To investigate the changes and clinical values of microRNA -22 （miR -22） expression in the invasion of hepatocellular carcinoma. Methods We analyze the expression of miR - 22 by quantitative real - time PCR in normal liver cell line LO2 and human hepatocellular carcinoma（HCC） cell lines with different metastatic potential, MHCC97L and HCCLM9. Then HCCLM9 was selected to transfect miR -22 inhibitor and mimics because of relatively low expression of miR - 22, the migration ability of HCCLM9 cell line was compared between before and af- ter transfection,the cell migration ability was detected by wound healing assay. Results The expression of miR - 22 was significantly reduced in I-CC cell lines compared with normal liver cell line LO2 （ P 〈 0.05 ）. Moreover, the expression of miR -22 in HCCLM9 cells with high invasiveness was lower than in MHCC97L cells with low invasiveness （ P 〈 0.05）. After transfection of miR - 22 inhibitor, the expression of miR - 22 in HCCLM9 cells decreased significantly（ P 〈 0.001 ）, and the migration ability was significantly enhanced （ P 〈 0. 001 ）. After transfection of miR - 22 mimics, the expression of miR -22 in HCCLM9 ceils increased significantly（ P 〈 0. 001 ）, and the cell migration ability was significantly diminished （ P 〈 0. 001 ）. Conclusion miR - 22 can inhibit the migration and invasion of hepato- cellular carcinoma cells, thereby to inhibit the metastasis of hepatocellular carcinoma.